


**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**


Attorney Docket Number	4239-68226-07
Application Number	10/559,825
Filing Date	December 2, 2005
First Named Inventor	Rachel Schneerson
Art Unit	2829 1645
Examiner Name	To be assigned Swartz

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
/RS/		US 2005/0271672 A1	08 Dec 2005	Schneerson et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
/RS/		WIPO/PCT	WO 02/057422 A2	25 July 2002	Schwartz

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
/RS/		Heitzmann et al., "Use of the Avidin-Biotin Complex for Specific Staining of Biological Membranes in Electron Microscopy," <i>Proc. Nat. Acad. Sci. USA</i> 71(9):3537-3541, 1974
/RS/		Itaya et al., "Cell Surface Labeling of Erythrocyte Glycoproteins by Galactose Oxidase and Mn ⁺⁺ -Catalyzed Coupling Reaction with Methionine Sulfone Hydrazide," <i>Biochemical and Biophysical Research Communications</i> 64(3):1028-1035, 1975
/RS/		Kozel et al., "mAbs to <i>Bacillus anthracis</i> capsular antigen for immunoprotection in anthrax and detection of antigenemia," <i>PNAS</i> 101(14):5042-5047, 2004
/RS/		Kubler-Kielb et al., "Chemical Structure, Conjugation, and Cross-Reactivity of <i>Bacillus pumilus</i> Sh18 Cell Wall Polysaccharide," <i>Journal of Bacteriology</i> 186(20):6891-6901, 2004
/RS/		Kubler-Kielb et al., "Additional Conjugation Methods and Immunogenicity of <i>Bacillus anthracis</i> Poly-γ-D-Glutamic Acid-Protein Conjugates," <i>Infection and Immunity</i> 74(8):4744-4749, 2006
/RS/		Rando et al., "Threshold Effects on the Concavavalin A-mediated Agglutination of Modified Erythrocytes," <i>The Journal of Biological Chemistry</i> 254(17):8318-8323, 1979

**EXAMINER
SIGNATURE:**

/Rodney Swartz/

DATE
CONSIDERED:

03/28/2007

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

02 DEC 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-68226-07
Application Number	To be assigned 10/459825
Filing Date	Herewith
First Named Inventor	Rachel Schneerson
Art Unit	To be assigned 1645
Examiner Name	To be assigned Swartz

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
/RS/		4,496,538	29 Jan 1985	Gordon et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
/RS/		WIPO/PCT	WO 01/60412 A2	23 Aug 2001	Genzyme Corp.

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
/RS/		Alkan et al., "Antigen recognition and the immune response: The Capacity of L-tyrosine-azobenzenearsonate to serve as a carrier for a macromolecular hapten," <i>Journal of Immunology</i> 107(2):353-358, 1971
/RS/		Devi et al., "Cryptococcus-neoformans Serotype A Glucuronoxylomannan-Protein Conjugate Vaccines: Synthesis, Characterization and Immunogenicity," <i>Infection and Immunity</i> 59(10):3700-3707, 1991
/RS/		Emmanuel et al., "Poly-gamma-D-glutamic acid as a template for functionalized water-soluble biomaterials," <i>Abstracts of Papers American Chemical Society</i> 219(1-2):BIOL 133, 2000, and 219 th Meeting of the American Chemical Society, San Francisco, California, March 26-30, 2000

EXAMINER
SIGNATURE:

/Rodney Swartz/

DATE

CONSIDERED:

03/28/2007

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

WR:jam 12/01/05 4239-68226-07 458535 E-343-2002/0-US-04

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-68226-07
	Application Number	10/559825
	Filing Date	Herewith
	First Named Inventor	Rachel Schneerson
	Art Unit	To be assigned 1645
	Examiner Name	To be assigned Swartz

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
/RS/		Goodman et al., "Immunochemical Studies on the Poly-gamma-D-glutamyl Capsule of <i>Bacillus anthracis</i> . 3. The Activity with Rabbit Antisera of Peptides Derived from the Homologous Polypeptide" <i>Biochemistry</i> 7(2):706-710, 1968
/RS/		King et al., "Preparation of Protein Conjugates via Intermolecular Hydrazone Linkage," <i>Biochemistry</i> 25:5774-5779, 1986
/RS/		Klaus et al., "The immunological properties of haptens coupled to thymus-independent carrier molecules: III. The role of the immunogenicity and mitogenicity of the carrier in the induction of primary IgM anti-hapten responses," <i>European Journal of Immunology</i> 5(2):105-111, 1975
/RS/		Leppla et al., "Development of an improved vaccine for anthrax," <i>Journal of Clinical Investigation</i> 110(2):141-144, 2002
/RS/		Pannifer et al., "Crystal structure of the anthrax lethal factor," <i>Nature</i> 414:229-233, 2001
/RS/		Pozsgay et al., "Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from <i>Shigella dysenteriae</i> type 1," <i>Proc. Natl. Acad. Sci. USA</i> 96:5194-5197, 1999
/RS/		Ramirez et al., "Production, recovery and immunogenicity of the protective antigen from a recombinant strain of <i>Bacillus anthracis</i> ," <i>Journal of Industrial Microbiology and Biotechnology</i> 28:232-238, 2002
/RS/		Rhie et al., "A dually active anthrax vaccine that confers protection against both Bacilli and toxins," <i>PNAS</i> 100(19):10925-10930, 2003
/RS/		Robbins et al., "Prevention of Systemic Infections, Especially Meningitis, Caused by <i>Haemophilus influenzae</i> Type b," <i>JAMA</i> 276(14):1181-1185, 1996
/RS/		Schneerson et al., "Preparation, Characterization, and Immunogenicity of <i>Haemophilus Influenzae</i> Type b Polysaccharide-protein Conjugates," <i>Journal of Experimental Medicine</i> 152(2):361-376, 1980
/RS/		Schneerson et al., "Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of <i>Bacillus anthracis</i> : A potential addition to the anthrax vaccine," <i>PNAS</i> 100(15):8945-8950, 2003
/RS/		Senyk et al., "Immune response to glucagons in conjugated form," <i>Immunochemistry</i> 9(2):97-110, 1972
/RS/		Shinefield et al., "Use of a <i>Staphylococcus Aureus</i> Conjugate Vaccine in Patients Receiving Hemodialysis," <i>The New England Journal of Medicine</i> 346:491-496, 2002

EXAMINER SIGNATURE: /Rodney Swartz/	DATE CONSIDERED: 03/28/2007
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-68226-07
Application Number	To be assigned 1645
Filing Date	Herewith
First Named Inventor	Rachel Schneerson
Art Unit	To be assigned 1645
Examiner Name	To be assigned Swartz

[illegible]

EXAMINER SIGNATURE: /Rodney Swartz/	DATE CONSIDERED: 03/28/2007
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	